#China #Shanghai #MXGP #Aphranel #MOYOM Biotech

Aphranel® Shines at MXGP Shanghai 2026

Aphranel®, a prominent regenerative aesthetics brand founded by MOYOM Biotech in China, made a significant presence as the official partner for the Shanghai leg of the FIM Motocross World Championship (MXGP) held from September 11 to 13, 2026. The event served as an ideal platform to unveil Aphranel®'s groundbreaking approach to facial aesthetics, captivating an audience far beyond the medical aesthetics community.

The Aphranel® exhibition at MXGP Shanghai attracted numerous visitors from the realms of motorsport and lifestyle, enchanted by its unique aesthetic design. Attendees eagerly explored the brand's offerings, taking photos alongside the impressive motorcycle displays, which highlighted the intersection of high-performance sports, cutting-edge innovation, and contemporary aesthetics.

The booth featured the brand's iconic green color intertwined with a butterfly-themed installation alongside exhibitions dedicated to motorcycles and motocross. A standout attraction was the Aphranel® Time Café, created under the slogan, “Take Control. Dare to Reveal Yourself.” This space garnered significant attention, evolving into a popular spot among photographers over the weekend.

Targeting a predominantly male audience, Aphranel® emphasized the importance of male facial aesthetics. Central to their showcase was the MagiCCrystal biostimulator, which utilizes calcium hydroxyapatite (CaHA) to sculpt facial structures based on individual anatomy, particularly around the forehead, nose, chin, and jawline. This precision-based approach accentuates facial proportions and contour definitions while preserving the unique features of each individual face.

Among the visitors was Zhang Xue, founder of the Chinese motorcycle brand ZXMOTO, highlighting a unique collaboration between two distinct Chinese brands within vastly different fields. The MagiCCrystal product resulted from a dedicated research program on calcium hydroxyapatite initiated by MOYOM Biotech back in 2013. Supported by China's national science and technology initiatives during the 13th Five-Year Plan, this innovative product received approval from the National Medical Products Administration (NMPA) in February 2025, officially classifying it as a Class III medical device. MagiCCrystal became the first facial biostimulator using calcium hydroxyapatite microspheres to be approved in China, garnering remarkable commercial success with over 200,000 syringes sold and distribution through more than 700 aesthetic clinics across the country.

By partnering with the MXGP, Aphranel® was able to create a setting conducive to linking long-term research with technical precision, resilience, and the rigorous standards behind their biomaterials while appealing to qualities highly appreciated in motorsport. This collaboration is part of a broader initiative by Aphranel® to showcase regenerative aesthetic technology developed in China to an international audience. Alongside efforts in biomaterials R&D and commercialization, the brand is expanding its initiatives into the realms of sports, design, and culture.

Looking ahead, Aphranel® aspires to continue its global expansion after the exciting weekend in Shanghai. Its philosophy of harmony with time aims to connect scientific endeavors with evolving perceptions of contemporary aesthetics, ensuring they remain at the forefront of the regenerative aesthetics revolution.